Related coverage linked through entity extraction aliases.
Mar 23, 2026
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Mar 18, 2026
A longitudinal study of 460,000 teenagers found that adolescent cannabis use increases the risk of developing bipolar and psychotic disorders by twofold, as well as raising risks for depression and anxiety.
Mar 18, 2026
The American Psychiatric Association will include biomarkers in the next DSM edition, though such markers remain unvalidated for routine clinical use. Research has spanned decades with limited adoption despite potential to guide treatment selection.
Mar 14, 2026
New research reveals how ketamine rewires brain receptors to rapidly relieve severe depression, while separate trials demonstrate success with personalized brain stimulation and targeted drug therapy for treatment-resistant cases.
Mar 14, 2026
A secondary analysis of the OPTIMUM trial found that higher doses of bupropion and prior fall history significantly increase fall risk in older adults with treatment-resistant depression receiving antidepressant augmentation.
Mar 10, 2026
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
Mar 10, 2026
Total spending on direct-to-consumer prescription drug advertising reached $9 billion in 2024, prompting renewed debate over whether such marketing should be legal. The U.S. and New Zealand remain the only developed nations allowing the practice.
Mar 09, 2026
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
Mar 06, 2026
New research links GLP-1 drugs like Ozempic to increased scurvy risk through appetite suppression and poor nutrition. University of Florida researchers are testing a GLP-1 implant for obese cats as feline obesity affects nearly 60% of US cats.
Mar 04, 2026
Recent studies demonstrate brain stimulation therapies can accelerate depression treatment to five days and low-dose lithium may slow cognitive decline in seniors with mild cognitive impairment.
Feb 21, 2026
The controversy over direct-to-consumer prescription drug advertising has gained renewed attention from the Trump administration and legislators, with spending reaching $9 billion in 2024 and debate centering on whether such ads benefit or harm consumers.
Feb 23, 2026
A phase 2 trial found that a single intravenous dose of dimethyltryptamine (DMT) alongside psychotherapy significantly reduced major depressive disorder symptoms, with effects lasting up to 6 months.
Feb 17, 2026
Compass Pathways announced positive results from its second Phase 3 trial of synthetic psilocybin COMP360 for treatment-resistant depression, showing a 3.8-point reduction in depression scores. The company plans to meet with the FDA to discuss a rolling approval application.
Feb 17, 2026
Cyrano Therapeutics announced positive Phase 2 FLAVOR trial results for CYR-064, an intranasal spray for persistent post-viral hyposmia. The trial met primary safety and secondary efficacy endpoints, supporting Phase 3 development in 2H 2026.
Feb 17, 2026
Recent studies reveal significant barriers in accessing mental health care for children and maternal health services, with nearly 25% of children's mental health needs going unmet and abortion restrictions linked to increased maternal deaths.
Feb 17, 2026
Compass Pathways reported positive phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant symptom reduction. The company plans to discuss FDA filing with a New Drug Application expected in Q4 2026.
Feb 17, 2026
Compass Pathways reports positive Phase 3 results for synthetic psilocybin in treatment-resistant depression, while a Phase 2 trial demonstrates rapid antidepressant effects from single-dose DMT. Both studies show modest efficacy signals amid growing pharmaceutical interest in psychedelic compounds.
Feb 16, 2026
The American Psychiatric Association released a roadmap for the future DSM in January 2026, proposing to incorporate biomarkers and rename the manual to reflect scientific scope. A new conceptual framework suggests using electrical and chemical signals to explain mental disorders and human intelligence.
Feb 14, 2026
A population-based study of over 1.27 million births found SSRI antidepressants during pregnancy increase gestational diabetes risk but reduce preterm birth and low birth weight risks, with effects independent of maternal depression.
Feb 13, 2026
Researchers at Icahn School of Medicine at Mount Sinai found that major depressive disorder shares key immune abnormalities with atopic dermatitis, particularly Th2 pathway activation. The team plans to test dupilumab in a clinical trial for depression.
